BioPharm America™ 2012 in Boston remains top biotech and pharma partnering event

September 26, 2012

Washington, DC; Carlsbad, CA and Boston, MA – September 26, 2012: The fifth annual international partnering conference, BioPharm America™ 2012, wrapped up last week in Boston. There were over 750 delegates representing 462 companies from 30 countries engaged in 1,846 one-to-one partnering meetings with 652 licensing opportunities, confirming BioPharm America as the premier destination for forming partnerships between emerging innovator and start-up companies, and large multinational firms.

"BioPharm America continues to bring the most talented, innovative leaders of biotech and pharma to Boston every year," said Carola Schropp, President of EBD Group. "The goal of partnering, the goal of this event, is the improvement of healthcare for all, and ultimately providing patients the treatments and therapies they need. This can only be achieved by coupling novel research with the right investor partners. That is what BioPharm America delivers year after year."

The dynamic program began with an announcement of the 2012 Fierce 15 by FierceBiotech Editor-in-Chief John Carroll, and a keynote address from David Meeker, President and CEO of Genzyme, a Sanofi company. Roundtable discussions on diagnostics, open access and diabetes, and spotlight and business development panels with topics ranging from major deals of 2012 to operationalizing external R&D featured high level executives and CEOs from leading pharmaceutical and biotech companies. Delegates were also some of the first to hear about the formation of TransCelerate BioPharma, a new non-profit organization focused on accelerating the development of new medicines that was announced by Carola Schropp on behalf of newly appointed interim CEO of TransCelerate, Garry Neil.

The event, organized by EBD Group, the leading partnering firm for the life science industry, was held September 19–21, 2012 at the Westin Boston Waterfront in Boston, MA in collaboration with the Massachusetts Biotechnology Council (MassBio).

"BioPharm America was once again a success for the local Massachusetts life sciences community and our colleagues from around the world," said Robert K. Coughlin, President and CEO of MassBio. "The discussion from industry leaders narrowed in on deconstructing the critical challenges the industry faces today and fleshing out potential opportunities for continued growth. The focus on partnering allowed stakeholders to make the connections they need to continue to grow, thrive, and solve unmet medical needs."

An impressive mix of companies, partners and local large pharmaceuticals attended BioPharm America 2012 including Alexion Pharmaceuticals, Amgen, AstraZeneca, Bayer HealthCare, Bristol-Myers Squibb, GlaxoSmithKline, Ironwood Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and Takeda.

View video highlights from BioPharm America 2012 online at

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Upcoming Events email!
For Email Marketing you can trust